INCYTE GENOMICS SIGNS AGREEMENT WITH ACCELRYS.
The agreement calls for Accelrys to functionally annotate these sequences with GeneAtlas(TM), the company's application for high throughput sequence and structure-based annotation. The results of the annotation will be delivered to Incyte in AtlasStore(TM), Accelrys' Oracle-based relational database for storing protein 3D annotations, as well as sequence, structural, chemical and functional information. In addition, Accelrys will provide Incyte with Discovery Studio(TM) data mining applications in order to access Atlas Store and view protein 3D annotations and structural models. By utilizing Discovery Studio compliant applications to view the structures, Incyte will become one of the first genetic research firms to access Accelrys' developing enterprise-wide solution for supporting integrated pharmaceutical disco very.
"We're very excited about this agreement and look forward to developing a long-standing relationship with Incyte - a pioneer and leader in genomic research," said Scott Kahn, Ph.D., general manager and senior vice president, Accelrys Life Science. "Based on our previous success using this proprietary technology to annotate 89% of the publicly available human genome, we expect that the information from these newly annotated proteins will facilitate Incyte's new therapeutic discovery and development initiative."
"Incyte has an appreciable number of proprietary gene sequences for which little is known about the possible functions of their encoded protein," said Robert Stein, M.D, Ph.D., president and chief scientific officer of Incyte . "Accelrys' high throughput technologies for predicting protein structure and recognizing similarities to other proteins of known function should be very useful in gaining a functional perspective on many of Incyte's proprietary gene sequences. Ultimately, this should help us identify pharmaceutical opportunities for our therapeutic discovery and development initiatives and to advance our gene-related intellectual property portfolio and information offerings."
About Incyte Genomics
Incyte Genomics, Inc. has the largest commercial portfolio of issued United States patents covering human, full-length genes and the proteins they encode and is leveraging its leading intellectual property and genomic information position to be a leader in therapeutic small molecule, secreted protein and antibody discoveries. In addition, Incyte has also developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and licenses pharmaceutically relevant intellectual property. These offerings facilitate pharmaceutical and biotechnology researchers in their drug discovery and development; including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease.
For more information, visit http://www.incyte.com.
Accelrys is a leading provider of software for computation, simulation, and the management and mining of scientific data used by biologists, chemists, and materials scientists for product design, drug discovery, and development. Accelrys' platform technology and consulting services enable enterprise -wide solutions tailored to today's leading research organizations. The company's three main centers of excellence are in San Diego, CA, Princeton, N J, and Cambridge, UK. These centers combine research and product development with facilities to support significant collaborative projects. Accelrys is a subsidiary of Pharmacopeia, Inc. (NASDAQ:PCOP) and was launched in Jun e 2001, combining leading software companies Molecular Simulations Inc., Synopsys Scientific Systems, Oxford Molecular, GCG, and Synomics Ltd.
For more information, visit http://www.accelrys.com or call (858)799-5393.
|Printer friendly Cite/link Email Feedback|
|Comment:||INCYTE GENOMICS SIGNS AGREEMENT WITH ACCELRYS.|
|Publication:||Online Product News|
|Date:||Jul 1, 2002|
|Previous Article:||OPENLINK'S VIRTUOSO 2.7 SUPPORTS ODBC/JDBC DATABASES.|
|Next Article:||EBT CONVERTS PAPER-BASED BENEFITS TO ELECTRONIC-BASED CARD.|
|ONLINE PROGRAM ACCELERATES MEDICAL RESEARCH PROGRAMS.|
|LION GETS NEW AND UPGRADED LICENSES FOR SRS.|